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Abstract 
 
Microbial contamination of multi-dose vials is one of the mechanisms by which 
transmission of pathogens to patients can occur in anaesthesia. Common practice at 
Chris Hani Baragwanath Academic Hospital (CHBAH) is to use boluses of a self-
prepared, multi-dose phenylephrine solution (referred to as the solution) to treat 
hypotension, due to the vasodilatory effects of a spinal anaesthetic, in stable patients 
undergoing a caesarean section.  
The aims of this study were to determine if there was microbial contamination of the 
solutions used at CHBAH and to evaluate if appropriate labelling and aspiration 
practices were adhered to with regard to the solutions.  
A sample was collected and the labelling data was documented from the solutions found 
in the obsteric theatres at CHBAH over a period of three months. The samples were 
sent to a laboratory for microbial investigation. 
Microbial contamination was identified in seven of 110 (6.36%) samples collected from 
the solutions. The name of the solution was indicated on all 110 (100%) containers and 
the concentration of the solution was indicated on 106 (96.36%) containers. The date 
the solution was prepared was indicated on 82 (74.55%) containers and the time the 
solution was prepared was indicated on 63 (57.27%) containers. Only nine (8.18%) of 
the healthcare workers that prepared the solutions confirmed it by placing a signature on 
the container. Labelling data was written directly on all 110 (100%) containers and a 
spike device was used in 71 (64.54%) containers. 
This study demonstrated microbial contamination of the solutions and that safe injection 
practices were not adhered to when intravenous medications were prepared and 
administered. This is important at CHBAH since a large proportion of South African 
patients are immunocompromised and susceptible to opportunistic infections. 
Inappropriate labelling of medications is a cause of medication administration errors and 
this may have serious legal implications for the anaesthetist.  
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Chapter 1: Overview of the study 
1.1 Introduction 
In this chapter the background, problem statement, aims and objectives, research 
assumptions, demarcation of study field, ethical considerations, research methodology, 
significance, validity and reliability, and study outline will be discussed. 
 
1.2 Background 
Anaesthetists are responsible for the safe use of anaesthetic-associated drugs (1). They 
play an important role in preventing microbial contamination of the drugs they use and 
preventing nosocomial infections. Failure in this role has a negative impact on the 
patient and the healthcare system.  
Recent studies have implicated anaesthetists in the transmission of pathogens to 
patients during regional (2, 3) and general (4, 5) anaesthesia. A significant number of 
anaesthetic-associated medication are contained in multi-dose vials (6). Microbial 
contamination of multi-dose vials (7-10) and anaesthetic equipment (11-14) are two of 
the main mechanisms by which patient-to-patient transmission of pathogens can occur 
in anaesthesia (15). 
International guidelines on preventing contamination of anaesthetic-associated 
medication (16, 17) clearly state that preservative-free vials are single-patient, single-
dose items. There is however evidence in the literature that single dose-vials can be 
used for multiple patients if safe injection practices and aseptic technique are adhered to 
(18). Uncontaminated multi-dose vials may be used until the manufacturer’s expiration 
date only if aseptic technique is used consistently. Each time a multi-dose vial is 
entered, aseptic technique should be used, including cleaning the multi-dose vial 
septum with alcohol and using a sterile needle and syringe (16).  
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Despite the above guidelines current infection control practices of anaesthetists working 
in developed countries falls short of accepted recommendations (15, 19-21). A matter of 
particular concern is the infection risk associated with the use of single-dose vials for 
multiple patients (22-24) and the use of multi-dose vials (7-10). The infection risk is due 
to unsafe injection practices. Reasons for non-compliance with regard to basic infection 
control practices in anaesthesia include ignorance, convenience and economical 
considerations (25). 
From the above it is clear that the use of single-dose vials for multiple patients and the 
use of multi-dose vials pose a risk for microbial contamination if safe injection practices 
are not adhered to. Most of the studies done on this subject focused on the anaesthetic 
community and their practices in developed countries.  
A review of the local literature with regards to the use of multi-dose vials in anaesthesia 
yielded only one study done by Morgan (26) at Chris Hani Baragwanath Academic 
Hospital (CHBAH). Morgan investigated the microbial contamination of a hyperbaric 
bupivicaine and fentanyl multi-dose preparation used for administering spinal 
anaesthetics to patients undergoing caesarean section. The results of this study 
suggested that the use of this multi-dose preparation for spinal anaesthesia was safe. 
However, strict aseptic technique was used to prepare and administer the preparation 
and the bupivicaine used in the preparation has antimicrobial properties (27, 28). This 
might not reflect everyday practice where strict aseptic technique is not always adhered 
to (15, 19-21). 
The correct labelling of medication in anaesthetic practice is a key element to safe 
medication administration (29). Inappropriate labelling of medication has been identified 
as a cause for medication administration errors in general (30, 31) and anaesthetic 
practice (32-34). Anaesthetists can be held legally accountable for medication 
administration errors and the administration of contaminated medication (35).  
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1.3 Problem statement 
Common practice at CHBAH is to use boluses of a self-prepared phenylephrine solution 
(referred to as the solution) to treat hypotension, due to the vasodilatory effects of a 
spinal anaesthetic, in stable patients undergoing a caesarean section. This solution then 
acts as a multi-dose vial which is used for multiple patients. 
The intravenous fluid vaculitres (normal-saline or Ringer’s lactate) used to prepare this 
solution do not contain any bactericidal or bacteriostatic agents. There is no evidence in 
the literature or in the package information from the manufacturer that phenylephrine 
has any anti-bacterial activity. 
It has been observed that this solution is often labelled incorrectly, used for more than 
12 hours on multiple patients and strict aseptic technique is not always adhered to when 
using this solution as a multi-dose vial. This solution thus has the potential for microbial 
contamination. 
Currently there is no formal protocol on the use of anaesthetic multi-dose vials in the 
South African literature or at the Anaesthetic Department at CHBAH. 
 
1.4 Aims and objectives 
1.4.1 Aims 
The aims of this study were to: 
• determine if there was microbial contamination of the solutions used at CHBAH   
• evaluate if appropriate labelling and aspiration practices were adhered to with 
regard to the solutions. 
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1.4.2 Objectives 
The objectives of this study were to:  
• determine whether there was any microbial contamination of the solutions and to 
identify the contaminating microorganisms 
• evaluate whether the name and concentration of the solutions were documented 
on the containers 
• evaluate whether the date and time the solutions were prepared was documented 
on the containers  
• evaluate whether the healthcare workers that prepared the solutions confirmed it 
by placing a signature on the containers  
• evaluate the labelling method of the solutions (i.e. written directly on the container 
or label stuck on container)   
• evaluate the aspiration method of the solutions (i.e. puncturing the rubber septum 
of the container with a needle or using a spike-device). 
 
1.5 Research assumptions 
The following definitions were used in this study: 
Aseptic technique: Any healthcare procedure in which added precautions, such as use 
of sterile gloves and instruments, were used to prevent contamination of a person, 
object or area by microorganisms (36). 
Disinfection: The process of destroying pathogenic organisms, or of rendering them 
inert, especially as applied to the treatment of inanimate materials to reduce or eliminate 
infectious organisms (37). 
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Healthcare worker: A healthcare worker refers to an individual that provides healthcare 
services to a patient . In this study the healthcare worker may be a medical docter or a 
nurse involved in the anaesthetic management of patients.   
Infection control practices: Policies and procedures used to minimise the risk of 
spreading infections, especially in hospitals and health care facilities (36).  
Labelling data: In this study it refers to the labelling information contained on the 
solution containers which included the name and concentration of the solution, the date 
and time the solution was prepared, the signature of the person who prepared the 
solution, the labelling method of the solution and the method of aspirating the solution 
from the container. 
Microbial contamination: Inclusion of microorganisms in or on an item used in the 
medical care of patients. In this study microbial contamination was considered as the 
presence of aerobic bacteria in the solutions. 
Microorganism: An organism that is microscopic or submicroscopic and cannot be 
seen by the naked eye. Examples of microorganisms include bacteria, viruses, fungi and 
protozoa (37). 
Multi-dose vial: In this study a multi-dose vial was considered as any kind of medication 
container that was used more than once and was kept for potential reuse (10). 
Multi-dose vial septum: This refers to the rubber stopper used to close the opening of 
a multi-dose vial and prevent macro-contamination of the vial. The rubber stopper can 
be penetrated with a needle multiple times. 
Pathogen: Any disease-causing microorganism (37). 
Safe injection practices: Injection procedures that aim to maintain basic levels of 
patient safety and provider protection (38). A safe injection does not harm the recipient, 
does not expose the provider to any avoidable risks and does not result in waste that is 
dangerous for the community (39). 
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Spike-device: A device, for example a needle or an intravenous catheter, left in the 
multi-dose vial septum to facilitate aspiration of medication.  
The solution: This is a solution prepared by adding 1 ml of phenylephrine (10 mg/ml) to 
199 ml of fluid (normal saline or Ringer’s lactate) to produce a phenylephrine solution 
(50 µg/ml). Boluses of this self-prepared, multi-dose phenylephrine solution are used to 
treat hypotension, due to the vasodilatory effects of a spinal anaesthetic, in stable 
patients undergoing a caesarean section. This solution then acts as a multi-dose vial 
which is used for multiple patients. 
 
1.6 Demarcation of study field 
This study was conducted in the two identical obstetric operating theatres at CHBAH 
(theatre 1 and theatre 2). This hospital is the second largest hospital in the world and 
occupies 0.70 km² with 3 200 beds and 6 760 staff members (40). It is located in the 
Soweto area of Johannesburg and it is one of the teaching hospitals for the University of 
the Witwatersrand. A total of 150 - 180 caesarean sections are performed per week in 
the obstetric operating theatres (41).  
 
1.7 Ethical considerations 
This study was a laboratory-based microbiological and checklist-based study concerning 
the solutions. No patients or healthcare workers were directly involved in the study. Care 
was taken to prevent identification of patients who received boluses of the solutions and 
healthcare workers who prepared and administered these solutions.  
Ethics clearance was obtained from the Human Research Ethics Committee (Medical), 
University of the Witwatersrand (Appendix 1). Approval for the conduction of this study 
was obtained from the Postgraduate Office, Faculty of Health Sciences, University of the 
Witwatersrand (Appendix 2). Permission to conduct this study at CHBAH was obtained 
from the Medical Advisory Committee of CHBAH (Appendix 3). Verbal consent to 
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conduct this study was obtained from the Head of the Department of Anaesthesiology 
and the theatre matron of the obstetric operating theatres at CHBAH. This study was 
conducted in accordance with the Declaration of Helsinki (42) and the South African 
Good Clinical Practice Guidelines (43). 
 
1.8 Research methodology 
1.8.1 Research design 
A prospective, descriptive research design was used for this study. 
 
1.8.2 Study population 
The study population was the solutions used to treat hypotension, due to the 
vasodilatory effects of a spinal anaesthetic, in stable patients undergoing a caesarean 
section, found in the two identical obstetric theatres at CHBAH (theatre 1 and theatre 2)  
 
1.8.3 Study sample 
Sample size 
Due to financial constraints the sample size of this study was limited to 110 samples. 
 
Sampling method 
A convenience sampling method was used for this study. 
 
Inclusion and exclusion criteria 
Inclusion criteria for this study were:  
• the solutions found in the obstetric theatres at CHBAH.  
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Exclusion criteria for this study were:   
• the solutions with < 10 ml of solution left in the container 
• any breach in the aseptic technique used during the collection and transportation 
of samples by the data collector.  
 
1.8.4 Data collection 
Data collected 
The following data was collected: 
• microbial contamination of the solutions 
• microorganisms isolated from the solutions 
• name and concentration of the solutions as documented on the containers 
• date and time the solutions was prepared as documented on the containers 
• if the healthcare workers that prepared the solutions confirmed it by signature on 
the containers 
• type of labelling method used on the solution containers (i.e. written directly on 
the container or label stuck on container) 
• method used to aspirate the solutions (i.e. puncturing the rubber septum of the 
container with a needle or using a spike-device). 
 
Data collection process 
Samples of the solutions were collected, labelled, stored and transported in an aseptic 
manner. Microbiological investigation of the samples was done by qualified laboratory 
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personnel using standard microbiological laboratory equipment and procedures. The 
labelling of the solutions was evaluated using a predetermined checklist.  
 
Data collector 
All of the data was collected by the researcher. 
 
Data collection period 
Data were collected over a three month period, from October to December 2012. 
 
1.8.5 Data analysis 
Data capturing was done using an Excel 2007 spreadsheet (Appendix 3). Descriptive 
and inferential statistics were used to analyse the data. Statistical analysis was 
performed using GraphPad InStat, a statistics programme. A p-value of < 0.05 was 
considered as statistically significant. 
 
1.9 Significance of the study 
Patient safety is a global healthcare issue affecting countries at all levels of 
development. Healthcare-associated infections and adverse events due to medication 
errors are common causes of preventable harm to patients (44). 
The World Health Organisation (WHO) Patient Safety programme identified research as 
a priority for patient safety (44). An international expert working group set up by the 
WHO Patient Safety programme produced a list of 50 global research priorities (45). 
Healthcare-associated infections and safe injection practices are among the top 
research priority areas (45). 
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The Helsinki Declaration on Patient Safety in Anaesthesiology has identified syringe 
labelling and infection control as part of their aims for improving patient safety in Europe 
(46). 
An audit of infection control practices at Charlotte Maxeke Johannesburg Academic 
Hospital theatres during 2011, identified breaches in anaesthetic infection control 
practices as a potential source of nosocomial infections (47, 48). Recommendations to 
improve anaesthetic infection control practices included the adequate labelling of 
medications and to avoid using multi-dose vials. 
It was of importance to investigate whether safe injection practices were adhered to 
when intravenous medications were prepared and administered. Unsafe injection 
practices expose patients to potentially harmful microorganisms. It is especially 
important at CHBAH since a large proportion of South African patients are 
immunocompromised and susceptible to opportunistic infections (49).  
If the results of this study demonstrated that there was microbial contamination of these 
solutions and that correct labelling practices were not adhered to, it would serve as 
motivation to change the current practice regarding the use of multi-dose medications in 
the operating theatres at CHBAH. 
 
1.10 Validity and reliability of the study 
The researcher collected, labelled, stored and transported all the samples in an aseptic 
manner. 
All the specimens were analysed at the Infection Control Services Laboratory, 
Department of Clinical Microbiology and Infectious Diseases, Witwatersrand School of 
Pathology, University of the Witwatersrand. The processing of the samples and 
identification of the microorganisms were done by qualified laboratory personnel using 
standard microbiological laboratory equipment and procedures. 
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A predetermined checklist was used to collect the labelling information from all of the 
solution containers. 
 
1.11 Study outline 
The chapters in this study include: 
• Chapter 1: Overview of the study 
• Chapter 2: Literature review 
• Chapter 3: Research methodology 
• Chapter 4: Results and discussion 
• Chapter 5: Study summary, limitations, recommendations and conclusion 
 
1.12 Conclusion 
In this chapter the background, problem statement, aims and objectives, research 
assumptions, demarcation of study field, ethical considerations, research methodology, 
significance, validity and reliability, and study outline were discussed. The next chapter, 
chapter 2, will provide a review of the literature. 
  
	  	  
12	  
Chapter 2: Literature review 
2.1 Introduction 
In this chapter the literature concerning patient safety, anaesthetic infection control 
practices relating to the use of multi-dose vials, the microbial contamination of multi-
dose vials as a mechanism for nosocomial infections, types of multi-dose vials 
implicated in microbial contamination, microorganisms cultured from contaminated multi-
dose vials, the safe use of multi-dose vials, medication administration errors relating to 
the use of multi-dose vials and the labelling of medication will be discussed. 
 
2.2 Patient safety 
2.2.1 General 
According to the WHO, tens of millions of patients suffer disabling injuries or death each 
year due to unsafe medical practices and care (44). Nearly one in ten patients are 
harmed while receiving healthcare in well-funded and technologically advanced hospital 
settings. There is however little evidence about the burden of unsafe medical practices 
and care in developing countries (44). 
 
2.2.2 The National Core Standards for health establishments in South 
Africa  
The National Health Act, 61 of 2003 (50) emphasises the need to foster good quality 
health services by developing structures to monitor the compliance of health 
establishments with health care standards. The Office of Standards Compliance 
developed the National Core Standards for Health Establishments in South Africa (51), 
which assists in the monitoring of service delivery.  
The National Core Standards has identified patient safety as an area where quality or 
safety might be at risk. Patient safety ensures quality nursing and clinical care, reduce 
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unintended harm to patients, prevent or manage adverse events which include 
healthcare associated infections, and support any affected patients or staff. 
Infection prevention and control programmes has been identified as key components to 
reduce healthcare associated infections. It is recommended by the National Core 
Standards that formal surveillance and reporting systems should be in place to aid this 
process. 
 
2.2.3 The WHO patient safety programme 
In 2004 the WHO launched a patient safety programme (WHO Patient Safety) in 
response to a World Health Assembly Resolution urging the WHO and member states to 
prioritize the problem of patient safety and to emphasise that it is a global healthcare 
issue. The WHO Patient Safety programme aims to coordinate, disseminate and 
accelerate improvements of patient safety worldwide (44). 
The WHO Patient Safety programme identified research as a priority for patient safety. 
Research concerning patient safety enables an understanding of why adverse events 
occur, how and to what extent patients are harmed and how to reduce patient harm (44). 
 
2.2.4 Global research priorities 
An international expert working group set up by the WHO Patient Safety produced a list 
of 50 global research priorities (45). These priorities identified areas of knowledge gaps 
and where knowledge would greatly improve patient safety and reduce harm. 
Healthcare-associated infections and safe injection practices are among the top six 
research priority areas in developing countries (45). 
A global patient safety campaign launched by the WHO, Clean Care is Safer Care, aims 
to acknowledge infection control as a solid and essential basis towards patient safety. 
This campaign supports the reduction of healthcare-associated infections and their 
consequences (52).     
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2.3 Anaesthetic infection control practices relating to the 
use of multi-dose vials 
2.3.1 General 
The guidelines of the South African Society of Anaesthesiologists (SASA) on the duties 
of an anaesthetist stipulates that an anaesthetist should take responsibility for the safe 
use of anaesthetic-associated drugs (1). 
Numerous studies investigating the infection control practices of anaesthetists working in 
developed countries have been done (15, 19-21). Of concern are the hygienic practices 
of anaesthetists relating to the use of multi-dose vials. This includes hand washing, 
wearing of gloves, disinfection of anaesthesia working surfaces, re-use of syringes for 
more than one patient and the disinfection of the multi-dose vial septum. These infection 
control practices will be briefly discussed with the focus on the use of multi-dose vials. 
 
2.3.2 Hand washing  
Hand washing after each patient prevents the contamination of medication and injection 
equipment (53, 54). No local data is available regarding the hand washing practices of 
South African anaesthetist.  
A survey done by Tait et al (19) investigating the infection control practices of 493 
anaesthetists in the United States of America (USA) showed that 95.2% of anaesthetists 
washed their hands after exposure to Human Immunodeficiency Virus (HIV) positive 
patients. Following exposure to patients’ body fluids, 97.5% washed their hands. Only 
58% however admitted to always washing their hands after exposure to low risk 
patients. A national survey undertaken by Ryan et al (15) describing the current infection 
control practices relating to 272 New Zealand anaesthetists showed that 5.2% rarely and 
1.1% never washed their hands between patients. Mikatti et al (21) did a survey of the 
hygienic practices of 145 consultant anaesthetists in the North-West region of the United 
Kingdom (UK). It was found that 14.7% of anaesthetic consultants rarely and 1.4% never 
washed their hands between patients. 
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2.3.3 Wearing of gloves 
The WHO guidelines advocate the use of gloves to reduce microbial contamination of 
healthcare equipment and medication as well as preventing patient-to-patient 
transmission of infections (55). Tait et al (19) showed that in the USA only 49.4% of 
anaesthetists always and 36.9% frequently used gloves during the administration of 
anaesthesia. The survey conducted by Ryan et al (15) in New Zealand showed that 
30.5% of anaesthetists always and 53.7% frequently wear gloves. It was found however 
that only 57.1% of New Zealand anaesthetists always and 38.7% rarely changed their 
gloves if they became contaminated. Mikatti et al’s (21) survey of consultant 
anaesthetists in the UK showed that only 14.5% always and 42.1% rarely used gloves. 
 
2.3.4 Disinfection of anaesthesia working surfaces 
The Association for Professionals in Infection Control and Epidemiology (APIC) position 
paper on safe injection, infusion, and medication vial practices in healthcare (56) 
recommends that medications should be stored and prepared in a clean area and on a 
clean surface. Hall (57) demonstrated that there is blood contamination of anaesthesia 
equipment and monitoring equipment in clinical use in operating theatres. This includes 
the anaesthesia machine table and the anaesthesia cart table, the main areas where 
anaesthetists prepare medication. Tait et al (19) found that of the respondents from their 
survey in the USA, 40.4% rarely and 20.1% never disinfected their anaesthesia working 
surfaces. This is similar to what Mikatti et al (21) found in their survey of anaesthetic 
consultants in the UK where 33.1% of respondents rarely and 18.7% never disinfected 
their anaesthesia working surfaces. 
 
2.3.5 Re-use of syringes for more than one patient 
According to the American Society of Anesthesiologists (ASA) Committee on 
Occupational Health Task Force on Infection Control a total of 33 outbreaks of patient-
to-patient transmission of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) were 
reported between June 1998 and June 2008 (16). The re-use of syringes and 
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contamination of medications and flush solutions were found to be the primary cause 
(16). A disturbing finding by Tait et al (19) was the percentage of anaesthetists in the 
USA who re-used syringes for more than one patient. In private practice 28% of 
anaesthetists and 7.3% of anaesthetists in university practice reported frequently or 
always re-using syringes for more than one patient. Mikatti et al (21) found that 6.9% of 
anaesthetic consultants in the UK re-used syringes for more than one patient. 
 
2.3.6 Disinfection of the multi-dose vial septum  
The APIC position paper (56) also recommends that the septum of multi-dose vials 
should be cleaned with an alcohol swab or other approved antiseptic swab. The septum 
of the multi-dose vial should be allowed to dry before inserting a sterile needle into the 
vial. Tait et al (19) showed that of the anaesthetists in the USA participating in their 
survey, 26.6% rarely and 7.8% never disinfected the septum of multi-dose vials. Similar 
results were shown in the survey by Mikatti et al (21). Among consultant anaesthetists in 
the UK 17.5% never and 21.2% rarely disinfected the septum of multi-dose vials. Ryan 
et al (15) showed that 54.4% of respondents in their study in New Zealand never 
disinfected the septum of multi-dose vials.  
 
2.4 Microbial contamination of multi-dose vials as a 
mechanism for nosocomial infections 
2.4.1 General 
The use of multi-dose vials in the healthcare setting is controversial. Presently there are 
conflicting results reported in the literature. Numerous case reports (23, 58, 59) and 
studies (8, 10) have implicated the use of single-dose vials for multiple patients and 
multi-dose vials in nosocomial infections. Recent studies investigating safe injection and 
medication vial usage showed that single-dose vials used for multiple patients and multi-
dose vials are safe and without infection risk if safe infection control practices are 
adhered to (18, 60-62). The contamination rates of multi-dose vials in the literature are 
	  	  
17	  
inconsistent, and range from 0% to 27% (63). The differences in these contamination 
rates of multi-dose vials might partly be due to methodological differences and the types 
of medications collected (10). 
 
2.4.2 Contamination of multi-dose vials in general practice 
Multi-dose vials have been implicated as the source of infection in multiple outbreaks of 
nosocomial infections locally and internationally.  
In May 2005 an outbreak of Klebsiella pneumoniae (K. pneumoniae) infections in a 
neonatal unit of a regional hospital in KwaZulu-Natal, South Africa, was attributed to 
contamminated intravenous glucose preparations (64). The blood cultures of 26 
neonates infected with K. pneumoniae remained positive despite the administration of 
appropriate antibiotics. The possible causes for the persistently positive blood cultures 
were investigated and the organism was found in intravenous glucose preparations 
being used. Unopened vials of these preparations were sterile. On enquiry the staff 
volunteered that they had used these preparations for multiple dosing despite the fact 
that the instructions on the label of the vials advise to the contrary.  
An outbreak of Staphylococcus aureus (S. aureus) joint and soft-tissue infections at a 
hospital in Tennessee, USA, in August 2001 was associated with injections from a multi-
dose lidocaine vial (65). A physician performed intra-articular and soft-tissue injections 
on 17 patients and five were subsequently hospitalised for infections at the injection site. 
S. aureus was isolated from four of the patients. From the ten patients injected with 
lidocaine and triamcinolone, five developed infections compared with none of the seven 
patients injected with triamcinolone only. A multi-dose vial of lidocaine was most likely 
the source for the transmission of infection in this outbreak. S. aureus was however not 
isolated from the multi-dose lidocaine vial as the vial was unavailable for testing. 
In 2008 an outbreak of K. pneumoniae and Enterobacter aerogenes (E. aerogenes) 
were reported at an outpatient pain management facility in New York, USA (23). Four 
confirmed patients were identified. Of the four patients, three had positive blood cultures 
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for K. pneumoniae and one patient had a positive blood culture for E. aerogenes. All 
confirmed patients had a sacro-iliac joint steroid injection procedure and one confirmed 
patient also had a greater trochanter bursa steroid injection procedure. Medications 
used for pain management procedures in these patients included a single-dose vial of 
bupivicaine (0.25% and 0.5%), triamcinolone and a contrast dye (iodixanol). The opened 
100 ml vial of iodixanol was found to be contaminated with E. aerogenes.  
Mattner et al (10) did a prevalence study of the bacterial contamination of multi-dose 
vials at a 1 300-bed tertiary hospital in Hannover, Germany, in 2001. Multi-dose vials 
were defined as all opened containers that had been used at least once and kept for 
potential re-use. On a specific day, infection control nurses collected all the opened vials 
from every ward. Data recorded for each vial included the type of medication, labelling, 
storage temperature, location and date of opening. Each vial was also tested for 
microbial contamination. A total of 227 multi-dose vials were collected from 47 wards. 
Two vials containing a saline solution cultured Staphylococcus epidermidis (S. 
epidermidis). This resulted in a contamination prevalence of 0.9% for the multi-dose 
vials. 
Motamedifar et al (7) investigated the prevalence of multi-dose vial contamination by 
aerobic bacteria in a teaching hospital in Iran in 2006. Multi-dose vials were defined as 
all opened vials that were used more than once. Infection control nurses collected all 
multi-dose vials daily from each ward over a four-month period. Data recorded for each 
vial included drug type, location, opening date, storage conditions and expiration date. 
Each vial was also tested for microbial contamination. A total of 637 multi-dose vials 
were collected from 36 wards. Bacterial contamination was identified in 36 of the multi-
dose vials. Bacteria cultured from the multi-dose vials included Pseudomonas 
maltophilia (P. maltophilia), which is now known as Stenotrophomonas maltophilia (S. 
maltophilia), Bacillus coagulans (B. coagulans), S. epidermidus, α and β haemolytic 
streptococci, Actinomyces viscosus (A. viscosus), Acinetobacter species, Streptococcus 
viridans (S. viridans), Micrococcus species and Serratia marcescens (S. marcescens). 
This resulted in a contamination prevalence of 5.6% for the multi-dose vials which is 
considerably higher than what was found in the study of Mattner et al (10).   
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2.4.3 Contamination of multi-dose vials in anaesthetic practice 
Multiple case reports of nosocomial infections due to the microbial contamination of 
multi-dose vials have been reported in regional (2, 3) and general anaesthesia (4, 66-
68). 
A review on nosocomial infections and infection control in regional anaesthesia by 
Schulz-Stϋbner et al (2) identified the use of contaminated multi-dose vials in the 
practice of regional anaesthesia as one of the mechanisms of nosocomial infection. A 
case report by Halaby et al (3) discussing a fatal bacterial meningitis after spinal 
anaesthesia implicated non-adherence to adequate aseptic precautions during neuraxial 
anaesthesia as an important factor in the development of iatrogenic bacterial meningitis.  
The use of intravenous induction agents and analgesic agents as multi-dose vials for 
general anaesthesia have been implicated in the patient-to-patient transmission of 
infections. The induction agent propofol in particular has been identified as the source of 
contamination in numerous case reports (66-69). Propofol is a lipid containing emulsion 
with no preservatives and is therefore at high risk of microbial contamination (68). 
Kuehnert et al (67) reported a S. aureus bloodstream infection outbreak amongst 
psychiatric patients undergoing Electro-Convulsive Therapy at a hospital in Mississippi, 
USA, due to bacterial contamination of propofol. Out of the nine patients who received 
Electro-Convulsive Therapy on a specific day, five developed S. aureus bloodstream 
infections as diagnosed on blood cultures. On the epidemic day a 100 ml vial of propofol 
was used for multiple patients. The propofol vial in question was unavailable for 
microbiological testing. It was suggested that breaks in infection control, such as the 
multi-dosing of propofol from a single vial, led to the outbreak. 
Tallis et al (70) reported two cases of patient-to-patient transmission of HCV through a 
contaminated multi-dose fentanyl vial in Victoria, Australia in 2002. In the first case a 
patient became infected with HCV after a general anaesthetic for an arthroscopy. It was 
discovered that the preceding patient on the list was an intravenous drug abuser and 
had HCV infection. The same vial of propofol and fentanyl was used for both patients. 
Contamination of either the propofol or the fentanyl led to cross-infection of the second 
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patient. In the second case two patients were infected with HCV after neurolept-
anaesthesia for a colonoscopy and gastroscopy respectively. The patient preceding the 
two newly infected patients was an intravenous drug abuser and it was found that he 
had HCV infection. A single 20 ml (1000 µg) vial of fentanyl was used for the entire 
endoscopy list. Contamination of the fentanyl vial with HCV led to the infection of the two 
patients. 
	  
2.5 Types of multi-dose vials implicated in microbial 
contamination  
2.5.1 General 
Multi-dose vials have a high risk of contamination due to the use of poor aseptic 
technique (9, 10, 19). Although some multi-dose vials contain preservatives, it must be 
noted that preservatives does not always prevent the growth of microorganisms (9, 71). 
Contaminated multi-dose vials have been implicated in the outbreak of nosocomial 
infections and the contamination of multi-dose vials in the hospital setting has been the 
subject of numerous prevalence studies. 
 
2.5.2 Outbreaks associated with specific multi-dose vials 
Contaminated multi-dose vials have been identified as the source of nosocomial 
infections in numerous outbreaks. Table 2.1 gives a comprehensive overview of the 
multi-dose vials implicated in outbreaks of nosocomial infections form 2000 to 2011. The 
table was compiled from data found at www.outbreak-database.com and 
www.pubmed.gov . These databases were searched for articles and case reports where 
multi-dose medication vials were the source of nosocomial infections. Medications most 
often involved in outbreaks include fentanyl (4, 70, 72, 73), heparin (74-78), heparin-
saline solutions (58, 79-83), propofol (69, 84-86) and saline (22, 87-92). Relevant 
reports and case studies will be discussed shortly and are highlighted in Table 2.1. 
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Contaminated vials of fentanyl have been implicated in at least four outbreaks of 
nosocomial infections. Germain et al (4) reported the patient-to-patient transmission of 
HCV through the use of multi-dose vials during general anaesthesia at a private surgical 
clinic in Western France in 2001. A multi-dose fentanyl vial became contaminated after a 
general anaesthetic to a patient with unknown HCV infection, most likely contracted from 
getting a tattoo. The same syringe and needle used on the infected source-patient was 
used to aspirate fentanyl from two different vials. The second contaminated vial was 
subsequently re-used for three other patients. The contamination could be explained by 
different factors including repeated aspirations and injections of materials from a 
common vial, sharing of the same anaesthetic vial among different patients, possible 
blood reflux in the catheter line, and presence of an infected source-patient at the onset 
of surgery. 
Although multi-dose vials of heparin contain preservatives, it has been implicated as the 
source of infection in numerous outbreaks of nosocomial infections. Yang et al (75) 
reported the outbreak of Burkholderia cepacia (B. cepacia) in a Taiwan hospital in 2007. 
A contaminated multi-dose vial of heparin, used to prepare a heparin-saline solution in a 
20 ml syringe that was used as a flush for central venous catheters, was identified as the 
source of the nosocomial infection. 
The use of a heparin-saline solution as a flush to maintain patency of intravenous 
catheters is controversial and it is still common practice in some institutions (93, 94). 
Heparin-saline solutions have also been implicated in nosocomial infections. Prospero et 
al (79) described the outbreak of Pseudomonas aeruginosa (P. aeruginosa) catheter- 
related bloodstream infections in a teaching hospital in Ancona, Italy, in 2004. It was 
found that the source of the infection was the heparin-saline solution that was used to 
flush intravenous catheters. This solution was prepared by adding 1 ml of heparin from a 
vial to 100 ml of saline solution by nursing personnel and was then commonly used as a 
flush for three to five days until it was finished. 
Propofol is a lipid containing emulsion that contains sodium metabisulfate, which is 
bacteriostatic, but not bacteriocidal. Propofol can still support the growth of 
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microorganisms as it is not an antimicrobially preserved product under the United States 
Pharmacopeial standards (68, 95). The use of contaminated propofol has been 
implicated in the outbreak of nosocomial infections. Muller et al (69) reported the 
outbreak of K. pneumoniae and S. marcescens bloodstream infections due to the use of 
contaminated propofol at a hospital in Rotterdam, Netherlands, in 2008. It was found 
that lapses in the aseptic preparation, handling and storage of the propofol led to its 
contamination. 
The use of saline solutions has been implicated in numerous outbreaks of nosocomial 
infections. Greeley et al (22) reported the outbreak of HBV infection at a haematology- 
oncology practice in New Jersey, USA, in 2009. It was found that a single vaculitre of 
saline was used as a flush for multiple patients and that it was the most likely source of 
contamination. Krause et al (89) reported the outbreak of HCV at a hospital in Florida, 
USA, in 1999. The results of this epidemiologic investigation suggested that a multi-dose 
saline vial, which might have been contaminated with the blood from another patient, 
was the source of the outbreak. Yu et al (92) documented the outbreak of nosocomial 
Enterobacter cloacae (E. cloacae) in a Neonatal Intensive Care Unit (NICU) in Taiwan, 
China, in 1997. Although there were multiple modes of transmission, a bottle of 
contaminated saline was identified as the initial source.  
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Table 2.1 Multi-dose vials implicated in nosocomial infections 2000 to 2011 
Multi-dose vial Pathogen Infection Patients Death Evidence for 
relatedness 
Year, 
reference 
Betamethasone S.marcescens Meningitis 
Spinal abcess 
Joint or bursa 
5 
5 
1 
3 Microbiologic 2006(96) 
Bupivicaine (spinal) S.salivarius Meningitis 1 1 Epidemiologic 2006(3) 
Dextrose- saline 
solution 
E.gergoviae BSI 11  Molecular 
biological 
2003(97) 
Distilled water Pseudomonas 
spp 
Endopthalmitis 17  Epidemiologic 2006(98) 
Fentanyl S.paucimobilis BSI 6  Microbiologic 2009(72) 
Fentanyl S.marcescens 
E.cloacae 
BSI 26  Molecular 
biological 
2002(73) 
Fentanyl HCV Hepatitis C 2  Epidemiologic 2002(70) 
Fentanyl HCV Hepatitis C 4  Epidemiologic, 
molecular 
biological 
2001(4) 
Glucose 
preparation 
K.pneumoniae BSI 26 22 Microbiologic 2005(64) 
Heparin* P.putida 
S.maltophilia 
BSI 32  Microbiologic 2008(74) 
Heparin* B.cepacia BSI 9  Microbiologic 2008(75) 
  UTI 2    
Heparin* HCV Hepatitis C 18  Epidemiologic 2005(76) 
Heparin* R.pickettii BSI 9  Molecular 
biological 
2003(77) 
Heparin* P.falciparum Malaria 1  Epidemiologic 2000(78) 
Heparin-saline 
solution 
P.aeruginosa BSI 4  Microbiologic 2006(79) 
Heparin-saline 
solution 
P.putida BSI 2  Molecular 
biological 
2005(80) 
Heparin-saline 
solution 
R.pickettii BSI 19  Epidemiologic, 
molecular 
biological 
2005(81) 
Heparin-saline 
solution 
P.fluorescens BSI 36  Epidemiologic, 
molecular 
biological 
2005(58) 
Heparin-saline 
solution 
S.marcescens BSI 12 7 Epidemiologic 2002(82) 
Heparin-saline 
solution 
HCV Hepatitis C 11  Epidemiologic, 
molecular 
biological 
2002(83) 
Insulin*  S.marcescens BSI 8 7 Epidemiologic, 
molecular 
biological 
2004(99) 
Iodixanol K.pneumoniae 
E.aerogenes 
BSI 
BSI 
3 
1 
 Microbiologic, 
molecular 
biological 
2008(23) 
Iohexol S.marcescens BSI 5  Epidemiologic 2005(24) 
Lidocaine* S.aureus Joint 5 1 Epidemiologic, 
molecular 
biological 
2003(65) 
	  	  
24	  
Methylprednisolone E. rostratum Meningitis 22 8 Microbiologic 2011(100)  
Methylprednisolone E.dermatitidis Meningitits 
Joint 
4 
1 
1 Epidemiologic, 
molecular 
biological 
2003(101) 
Propofol K.pneumoniae 
S.marcescens 
BSI 7 0 Microbiologic 2010(69) 
Propofol E.cloacae BSI 4 2 Epidemiologic, 
molecular 
biological 
2002(84) 
Propofol HCV Hepatitis C 2  Epidemiologic 2002(70) 
Propofol S.marcescens BSI 
Wound 
infection 
5 
2 
2 Molecular 
biological 
2001(85) 
Propofol HCV Hepatitis C 5  Epidemiologic, 
molecular 
biological 
2001(86) 
Saline HBV Hepatitis B 21  Epidemiologic, 
molecular 
biological 
2009(22) 
Saline HCV Hepatitis C 16 2 Epidemiologic 2006(87) 
Saline K.oxytoca BSI 3  Epidemiologic, 
molecular 
biological 
2004(88) 
Saline HCV Hepatitis C 5  Epidemiologic, 
molecular 
biological 
2003(89) 
Saline HCV Hepatitis C 17  Epidemiological, 
molecular 
biological 
2003(90) 
Saline HCV Hepatitis C 2  Molecular 
biological 
2002(91) 
Saline HCV Hepatitis C 95  Epidemiological, 
molecular 
biological 
2001(102) 
Saline E.cloacae BSI 
Meningitits 
19 
4 
3 
4 
Epidemiologic, 
molecular 
biological 
2000(92) 
Saline HBV Hepatitis B 30  Molecular 
biological 
2000(103) 
TPN C.albicans BSI 8  Molecular 
biological 
2006(104) 
BSI- Blood Stream Infction; HCV- Hepatitis C Virus; UTI- Urinary Tract Infection; HBV- Hepatitis B Virus; TPN- Total Parenteral 
Nutrition 
* Vial contains preservative 
Sources:  www.outbreabreak-database.com, Mattner et al (10) 
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2.5.3 Specific multi-dose vials contaminated in hospitals 
The study done by Mattner et al (10) investigating the bacterial contamination of multi-
dose vials in a tertiary hospital in Hannover, Germany, showed a contamination 
prevalence of 0.9%. Of the 227 multi-dose vials collected, 77 vials contained saline 
solution, 41 vials contained heparin, 16 vials contained glucose, 16 vials contained 
sterile water for injection, 32 vials contained insulin and 45 vials contained 
miscellaneous medications (catecholamines, atropine, antibiotics, midazolam, 
furosemide, potassium chloride, iopromide and some others). About 50% of all the multi-
dose vials contained no preservatives. From two vials containing a saline solution, S. 
epidermidis was cultured. 
Motamedifar et al (7) investigated the prevalence of multi-dose vial contamination by 
aerobic bacteria in a major teaching hospital in Shiraz, Iran. The prevalence of multi-
dose vial contamination by bacteria was 5.6%, much higher than what was found in the 
study done by Mattner et al (10). A total of 637 multi-dose vials were collected. The 
medication types were mainly potassium chloride (KCl), saline, sodium bicarbonate, 
calcium carbonate, insulin and sterile water for injection. The most frequently 
contaminated solutions were KCl, sodium bicarbonate and saline (7). The data in Table 
2.2 shows the contaminated multi-dose vial and the isolated pathogen. There was no 
mixed contamination in any of the multi-dose vials. 
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Table 2.2 Contaminated multi-dose vials and pathogens isolated 
Multi-dose vial Pathogen 
KCl S. maltophilia, B. coagulans, S. epidermidis,          
A.viscosus, Acinetobacter sp, S. epidermidis, 
Micrococcus sp, Corynebacterium sp,                    
S.marcescens,α haemolytic streptococci,               
S. viridans  
Saline B.coagulans,S.epidermidis,S.viridans 
Sodium bicarbonate S.viridians, S.epidermidis, β haemolytic 
streptococci, Micrococcus sp, Acenitobacter sp,    
B. coagulans 
Calcium carbonate S. epidermidis 
Insulin* β haemolytic streptococci 
Sterile water for injection α haemolytic streptococci, S. epidermidis  
* Vial contains preservative 
Source: Motamedifar et al (7) 
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2.6 Microorganisms cultured from contaminated multi-dose 
vials 
2.6.1 General 
Bacterial, viral, fungal and protozoal contamination of multi-dose vials has been reported 
in the literature (Table 2.1). This is concerning in the South African healthcare setting 
since a large portion of the patients are immunocompromised and susceptible to 
opportunistic infections (49). 
 
2.6.2 Bacteria 
Bacteria are a common pathogen involved in the contamination of multi-dose vials as 
Table 2.1 shows. S. marcescens is most commonly involved in contamination of multi-
dose vials, followed by Enterobacter cloacae, K. pneumoniae, Ralstonia pickettii, 
Pseudomonas putida and S. aureus.    
The study conducted by Mattner et al (10) showed that cultures from two saline solutions 
were positive for S. epidermidis. The pathogens involved in the contamination of multi-
dose vials in the study of Motamedifar et al (7) are shown in Table 2.2. 
 
2.6.3 Viruses 
HBV and HCV have been the most common viruses associated with the contamination 
of multi-dose vials as shown in Table 2.1. 
Katzenstein et al (105) investigated the nosocomial transmission of HIV in an outpatient 
clinic in Copenhagen, Denmark, in 1996. They found that the most likely source of 
infection was a contaminated multi-dose saline solution. This is of particular concern 
since there is a high incidence of HIV-infection in the South African population (49, 106). 
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2.6.4 Fungi 
Welbel et al (107) reported on the Candida parapsilosis (C. parapsilosis) bloodstream 
infection outbreak in a Neonatal ICU (NICU) in Louisiana, USA, during 1991. A cohort 
study identified liquid glycerine multi-dose bottles, which were used to administer 
suppositories to NICU infants, as a risk factor for C. parapsilosis bloodstream infection.  
 
2.6.5 Protozoa 
Al-Saigul et al (78) reported a case where a patient developed nosocomial malaria due 
to the use of a contaminated multi-dose heparin vial in a hospital in Riyadh, Saudi 
Arabia, in 1997. 
 
2.7 The safe use of multi-dose vials 
2.7.1 General 
Multiple reports in the literature have implicated multi-dose vials as the source of 
infection in nosocomial outbreaks. In contrast, recent studies have shown that multi-
dose vials, and even single-dose vials used for multiple patients, can be used safely if 
safe injection and medication vial utilisation practices are adhered to. 
  
2.7.2 Uncontaminated multi-dose vials in general practice 
A study done by Manchikanti et al (18) investigated the infection control practices for 
interventional pain management procedures at a private interventional pain practice in 
the USA from May 2008 to December 2009. A total of 3 179 patients participated in the 
study and 18 472 procedures were carried out. Correct precautions and simple infection 
control measures were adhered to for each procedure. No infections of any significance 
were noted. It was shown that there is no risk with the use of single-dose vials for 
multiple patients and multi-dose vials if safe injection practices are adhered to.  
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Chen et al (61) evaluated the sterility, stability and efficacy of bevacizumab that was 
stored in multi-dose vials for six months. An aseptic technique was used each time 
bevacizumab was withdrawn from the multi-dose vial. This included disinfecting the vial 
septum with 10% povidone-iodine solution and an isopropyl alcohol wipe each time the 
vial was punctured, using a new needle and syringe each time. No microbial growth was 
obtained from any of the bevacizumab multi-dose vials. 
Lin et al (62) reported on the safety of multi-dose vials after routine clinical use for 
immunotherapy. Safe injection practices were adhered to when each multi-dose vial was 
used. A total of 136 multi-dose vials were cultured for aerobic and anaerobic bacteria. 
No microorganisms were cultured. 
  
2.7.3 Uncontaminated multi-dose vials in anaesthetic practice 
Morgan (26) investigated the microbial growth in a self-prepared mixture of hyperbaric 
bupivicaine and fentanyl in a multi-dose syringe in the operating theatre environment in 
Johannesburg, South Africa, in 2009. All mixtures were prepared by the researcher 
using an aseptic technique and contained fentanyl 10 µg/ml, bupivicaine 4 mg/ml and 
dextrose 64 mg/ml. Syringes were divided into pairs, a control syringe and a multi-dose 
syringe. Samples were withdrawn aseptically by a single person at the beginning and at 
the end of a 12-hour period from the control syringe, and hourly from the multi-dose 
syringe. For each syringe pair, both samples from the control syringe and four of the 
samples from the multi-dose syringe were submitted for microbial culture. A total of 119 
samples were submitted for microbial culture and one sample was positive for microbial 
growth. The positive sample was taken from a multi-dose syringe at the beginning of the 
study period (0 hours) and showed S. aureus growth. Subsequent samples from the 
same multi-dose syringe showed no microbial growth. Morgan postulated that the 
culture medium that yielded the microbial growth might have been contaminated since 
subsequent samples from the same multi-dose syringe were sterile or that the 
bupivicaine in the mixture, that has antimicrobial activity against some pathogens, 
inhibited any further microbial growth and produced subsequent sterile samples. The 
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researcher used a strict aseptic technique to prepare and aspirate all the samples of the 
hyperbaric bupivicaine and fentanyl mixture. The results of this study suggest that the 
aseptic use of multi-dose syringes for spinal anaesthesia could be safe, however it might 
not reflect the techniques used in everyday practice. 
Arrington et al (6) investigated whether an alteration in the medication aspiration 
technique of anaesthetists could cause a significant difference in the incidence of multi-
dose vial contamination in a theatre complex in the USA, in 1990. The control group 
consisted of multi-dose vials collected from staff anaesthetists at the end of each day. A 
single needle and syringe were used for a specific multi-dose vial throughout the day in 
the control group. The case group consisted of multi-dose vials collected from the four 
investigators at the end of each day. A new needle was used each time a multi-dose vial 
was punctured and a single syringe was used for a specific multi-dose vial throughout 
the day in the case group. Guaiac testing, using Hemoccult slides and developer, was 
performed on each collected multi-dose vial to evaluate for the presence of blood 
contamination. A multi-dose vial was considered positive for blood contamination if 
traces of blue appeared on the Hemoccult slide. The control group had a blood 
contamination rate of 2.24% where as the case group had a blood contamination rate of 
0.27%. A chi-square test on the data demonstrated a significant (p < 0.05) difference 
between the control and case groups suggesting that the medication aspiration 
technique of anaesthetists does influence the incidence of multi-dose vial contamination.   
The research showed that there was blood contamination of the multi-dose vials 
suggesting that contaminated medication may then be injected into patients. 
 
2.7.4 Guidelines for the safe use of multi-dose vials 
The Centres for Disease Control and Prevention (CDC) (108) and the WHO (53) have 
made recommendations for the use of multi-dose vials. These recommendations 
include: (1) Refrigerate multi-dose vials after they are opened if recommended by the 
manufacturer. (2) Clean the septum of the multi-dose vial with 70% alcohol before 
inserting a device into the vial. (3) Use a sterile device to access a multi-dose vial and 
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avoid touch contamination of the device before penetrating the septum. (4) Discard the 
multi-dose vial if sterility is compromised. (5) A needle or other device should never be 
left inserted into a medication vial septum for multiple uses as this provides a direct 
route for microorganisms to enter the vial and contaminate the fluid. 
The APIC position paper on safe injection, infusion, and medication vial practices in 
healthcare (56) strongly supports adherence to the following practices when using multi-
dose vials: (1) Perform hand hygiene before manipulating medication. (2) Use aseptic 
technique when handling medication. (3) Store and prepare medications in a clean area 
on a clean surface. (4) Follow manufacturer’s instructions for storage and use. (5) 
Always use a new sterile syringe and needle when entering a vial. (6) Clean the vial 
septum using friction and 70% isopropyl alcohol, ethyl alcohol, iodophor or other 
approved antiseptic swab. (7) Allow the septum to dry before inserting any device into 
the vial. (8) Never leave a needle, cannula or spike-device (even if it has a one-way 
valve) inserted into a medication vial septum because it leaves the vial vulnerable to 
contamination. (9) Discard the vial if the sterility is in question or according to 
manufacturer’s expiration date. 
The ASA Committee on Occupational Health and Infection Control have made 
recommendations for preventing contamination of medications during the practice of 
anaesthesia (16). Some of the recommendations for safe injection practices regarding 
the use of multi-dose vials include: (1) Use appropriate aseptic technique and hand 
hygiene to avoid contamination of injection equipment. (2) Use a sterile syringe and 
needle each time any medication or solution is accessed. (3) Disinfect the septum of a 
multi-dose vial with an alcohol swab or appropriate disinfectant before entering. (4) Store 
medications and solutions in accordance with the manufacturer’s recommendations. (5) 
Discard multi-dose vial if sterility is compromised. 
Facilities should develop a policy and procedure for their institution after reviewing and 
weighing these recommendations, implement an education and competency evaluation 
program for staff and consider audits for adherence to the facility’s policy (56). 
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Currently SASA does not have an official standpoint on the use of multi-dose vials but it 
does not endorse the practice of sharing single-dose vials between multiple patients 
(109, 110). 
 
2.8 Medication administration errors relating to the use of 
multi-dose vials 
2.8.1 General 
Medication errors are a common problem in the health care system and can be harmful 
to the patient and increase healthcare costs (111). There are two main types of 
medication errors: medication prescribing errors and medication administration errors 
(112). The safe administration of medication to a patient is a vital part of anaesthetists’ 
responsibilities (1).  
 
2.8.2 Medication administration errors in general practice 
Cousins et al (30) reported on the medication errors in intravenous drug preparation and 
administration in hospitals in the UK, Germany and France in 2004. Pharmacy staff 
directly observed the preparation of 824 doses and administration of 798 doses by 
nurses. Common medication administration errors included the wrong diluents (1%, 49% 
and 18% of doses administered in the UK, German and French hospitals respectively), 
preparation not mixed correctly (data not collected, 79%, 1%), wrong dose (1%, 2%, 
5%), wrong route (1%, 1%, 1%), wrong infusion rate (48%, 21%, 5%), inadequate 
aseptic technique (100%, 58%, 19%) and incorrect labelling (43%, 99% and 20%). Lack 
of appropriate labelling was a frequent error. Labelling errors included name of drug 
missing, dose missing, name of patient missing, time of preparation missing, and label 
absent or incomplete. 
A study done by Gokhman et al (31) reported on the medication errors during medical 
emergencies in a large tertiary care, academic medical centre in Pittsburgh, USA, from 
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March 2009 to February 2010. A pharmacist directly observed the medication use of the 
Medical Emergency Team treating 50 patients experiencing a medical emergency. A 
total of 186 doses were observed and 296 errors were identified. Of these, 196 errors 
(66%) were inappropriate aseptic technique. Of the remaining 100 errors, 46% were 
prescribing errors, 28% administration technique errors, 14% labelling errors, 10% drug 
preparation errors and 2% dose errors.    
The prevalence study done by Mattner et al (10) investigating the bacterial 
contamination of multi-dose vials showed that appropriate labelling practices were not 
adhered to. Of the 227 multi-dose vials collected, 113 (50%) were not dated. The 
medication type was not indicated on two multi-dose vials and the concentration of the 
medication was not indicated on seven multi-dose vials. Of the 114 (50%) dated multi-
dose vials, 15 (13%) had expired. 
 
2.8.3 Medication administration errors in anaesthetic practice 
The risk of medication administration errors might be higher in anaesthesia than in other 
disciplines due to the large number of drugs administered by anaesthetist during their 
career (113). Most anaesthetists have been or will be involved in medication 
administration errors during their career (33). 
A study done by Orser et al (114) investigated the medication errors in anaesthetic 
practice of 687 anaesthetist from Canada from 1995 through to 1997. A self-reporting 
survey was mailed to members of the Canadian Anaesthesiologists’ Society. Surveys 
from 687 anaesthetists revealed that 85% had experienced at least one drug error or 
near drug error (event that almost involved the wrongful administration of a drug). The 
misidentification of a syringe (70.4%) and the misidentification of the label (46.8%) were 
the most common causes for drug error.  
Llewellyn et al (34) investigated the drug administration errors of anaesthetists at three 
teaching hospitals in South Africa from 2005 to 2006. Anaesthetists working at the three 
hospitals were asked to complete a self-reporting survey for every anaesthetic 
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performed during a six-month period. Anaesthetist were asked if a drug error or a near 
drug error had occurred and the details thereof. A total of 30 412 anaesthetics were 
performed and survey-forms were completed in 53% of anaesthetics. The combined 
incidence for drug errors and near drug errors was reported as 1 in 274 anaesthetics. 
Misidentification of syringes accounted for 21.3% of all errors and drug ampoule 
misidentification accounted for 36.9% of errors. In the studies done by Orser et al (114) 
and Llewellyn et al (34) a self-reporting survey was used to assess the prevalence of 
medication administration errors amongst anaesthetists. Limitations of self-reporting 
studies include the respondent being too embarrassed to answer a question truthfully.   
Strategies suggested to reduce the incidence of medication administration errors in 
anaesthesia include medication safety education and awareness programs, re-reading 
labels on medication containers, cross-checking medication labels with a second person 
or a device, clear labelling of all medication containers, adopting the international colour-
coded labelling system and improving the organisation of drug drawers and work space 
(32-34, 114).  
 
2.9 Labelling of medication 
The correct labelling of medication in anaesthetic practice is a key element to safe 
medication administration (29). The Helsinki Declaration on Patient Safety in 
Anaesthesiology (46) declared syringe labelling as one of their aims for improving 
patient safety in Europe.  
The labelling of medication is often not done or is incomplete (30, 115). Inappropriate 
labelling of medication has been identified as a cause for medication administration 
errors in general (30, 31) and anaesthetic practice (32-34).  
Recommendations regarding safe labelling practices have been made by international 
organisations (115-120) as well as individual researchers (32, 34). 
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Labelling recommendations for medication containers (syringes, bags, bottles and 
bowls) include colour coded labels for medication classes, patient name, patient 
identifier, medication added to the container, amount of medication added (including 
units), total volume of diluent in container (ml), concentration (units/ml), date and time 
prepared, prepared by (signature), checked by (signature) and route of administration 
(29, 120). Labels on fluid bags and bottles should be placed on the front and the name 
of the fluid, batch number and expiry date should remain visible (120). Labels on 
syringes should be placed parallel with the long axis of the syringe barrel taking care not 
to cover the graduations (120).    
The Medicines and Related Substances Control Act of South Africa clearly states that 
the name of the medical practitioner, dentist, pharmacist, pharmacy or hospital that 
prescribe or prepare medication must be indicated on the label of medicines intended for 
administration to humans (121). 
It is recommended that stick-on, colour-coded labels are used for intravenous 
anaesthetic medications (122). Writing directly onto the container should be avoided as 
the ink can leach from the polyvinyl chloride (PVC) container into the intravenous fluid 
and has been shown to be toxic to animals (123). 
A study done by Webster et al (124) assessed a new anaesthetic drug administration 
system at two tertiary hospitals in New Zealand from 1998 to 2003. Features of the new 
system included labels with the class and generic name of each drug in clear lettering, a 
barcode on each drug container and the use of the international colour-code standard 
for anaesthetic drugs on labels. Fewer medication administration errors occurred with 
the new system than with conventional methods (p= 0.002). 
Porat et al (122) investigated the use of colour-coded labels for intravenous high-risk 
medications and intravenous lines to improve patient safety at a tertiary hospital in 
Jerusalem, Israel, during 2007. The new colour-coded label method was compared with 
the current labelling method (adhesive paper with black print on a white background and 
writing directly on the container with a marker pen). A laboratory simulation imitating an 
ICU was designed and the safety of medication treatment and overall duration of nurses’ 
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orientation with drugs and intravenous lines were measured. The use of the new colour-
coded label method improved identification of intravenous bags (p< 0.001), reduced time 
required for description of medication and intravenous lines (p= 0.04), improved 
identification of medication errors (p= 0.03) and reduced the average performance time 
for overall tasks (p< 0.0001). 
A research doctorate by Jansen (35) regarding the legal liability arising from medication 
errors emphasises that healthcare workers can be held legally accountable for errors 
occurring with the dispensing (which includes the labelling of medication), preparation 
and administration of medication. Healthcare workers can only administer medication 
that was appropriately checked by the healthcare worker. 
 
2.10 Summary 
From the literature it is clear that the use of multi-dose vials pose a risk of microbial 
contamination if safe injection practices are not adhered to. Bacterial, viral, protozoal 
and fungal pathogens have been implicated in the contamination of multi-dose vials. 
Despite safe injection guidelines the infection control practices of anaesthetists fall short 
of accepted recommendations. Recent studies have shown that multi-dose vials can be 
used safely if safe injection practices are adhered to. Safe injection practices include the 
correct labelling of medication containers. 
 
2.11 Conclusion 
This chapter discussed the literature concerning patient safety, anaesthetic infection 
control practices relating to the use of multi-dose vials, the microbial contamination of 
multi-dose vials as a mechanism for nosocomial infections, types of multi-dose vials 
implicated in microbial contamination, microorganisms cultured from contaminated multi-
dose vials, safe use of multi-dose vials and medication administration errors relating to 
the use of multi-dose vials. In the next chapter, chapter 3, the research methodology of 
this study will be discussed.  
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Chapter 3: Research methodology  
3.1 Introduction 
In this chapter the problem statement, aims and objectives, ethical considerations, 
research methodology and the validity and reliability of this study will be discussed. 
Discussion of the research methodology will include the research design, study 
population, study sample, data collection and data analysis of this study. 
 
3.2 Problem statement 
Common practice at CHBAH is to use boluses of a self-prepared phenylephrine solution 
(referred to as the solution) to treat hypotension, due to the vasodilatory effects of a 
spinal anaesthetic, in stable patients undergoing a caesarean section. This solution then 
acts as a multi-dose vial which is used for multiple patients. 
The intravenous fluid vaculitres (normal-saline or Ringer’s lactate) used to prepare this 
solution do not contain any bacteriocidal or bacteriostatic agents. There is no evidence 
in the literature or in the package information from the manufacturer that phenylephrine 
has any anti-bacterial activity. 
It has been observed that this solution is often labelled incorrectly, used for more than 
12 hours on multiple patients and strict aseptic technique is not always adhered to when 
using this solution as a multi-dose vial. This solution thus has the potential for microbial 
contamination. 
Currently there is no formal protocol on the use of anaesthetic multi-dose vials in the 
South African literature or at the Anaesthetic Department at CHBAH. 
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3.3 Aims and objectives 
3.3.1 Aims 
The aims of this study were to: 
• determine if there was microbial contamination of the solutions used at CHBAH   
• evaluate if appropriate labelling and aspiration practices were adhered to with 
regards to the solutions. 
 
3.3.2 Objectives 
The objectives of this study were to:  
• determine whether there was any microbial contamination of the solutions and  to 
identify the contaminating microorganisms 
• evaluate whether the name and concentration of the solutions were documented 
on the containers 
• evaluate whether the date and time the solutions were prepared was documented 
on the containers  
• evaluate whether the healthcare workers that prepared the solutions confirmed it 
by placing a signature on the containers  
• evaluate the labelling method of the solutions (i.e. written directly on the container 
or label stuck on container)   
• evaluate the aspiration method of the solutions (i.e. puncturing the rubber septum 
of the container with a needle or using a spike-device). 
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3.4 Ethical considerations 
This study was a laboratory-based microbiological and checklist-based study concerning 
the solutions. No patients or healthcare workers were directly involved in the study. Care 
was taken to prevent identification of patients who received boluses of the solutions and 
healthcare workers who prepared and administered these solutions.  
An application to the Human Research Ethics Committee (Medical) of the University of 
the Witwatersrand for the clearance of this study was submitted (Appendix 1). Approval 
for the conduction of this study was obtained from the Postgraduate Office, Faculty of 
Health Sciences, University of the Witwatersrand (Appendix 2). Permission to conduct 
this study at CHBAH was obtained from the Medical Advisory Committee of CHBAH 
(Appendix 3). Verbal consent to conduct this study was obtained from the Head of the 
department of Anaesthesiology and the theatre matron of the obstetric operating 
theatres at CHBAH. This study was conducted in accordance with the Declaration of 
Helsinki (42) and the South African Good Clinical Practice Guidelines (43). 
 
3.5 Research methodology 
3.5.1  Research design 
Burns & Grove (125) described a research design as the blueprint for a study. According 
to Brink (126) a research design determines the methods by which the researcher 
obtains subjects, collects data, analyses data and interprets results.  
Samples of the solution will undergo microbiological investigation and the labelling data 
of the solution will also be observed. A prospective, descriptive research design was 
chosen for this study.  
A prospective study design is described by Brink (126) as measuring the variables that 
will be occurring during the study.  
Brink (126) defined a descriptive study as a research study in which phenomena are 
described or the relationship between variables is examined and no attempt is made to 
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determine cause-and-effect relationships. The labelling data on each of the solutions 
from which a sample was taken for microbiological investigation was documented on a 
data collection form (Appendix 3). A standardised checklist, derived from labelling 
recommendations made by the Australian Commission on Safety and Quality in Health 
Care (120), was used to document the labelling data. A checklist is a structured 
observational technique used to establish whether a behaviour occurred (125).  
 
3.5.2 Study population 
The study population was the solutions used to treat hypotension, due to the 
vasodilatory effects of a spinal anaesthetic, in stable patients undergoing a caesarean 
section found in the two identical obstetric theatres at CHBAH (theatre 1 and theatre 2). 
 
3.5.3  Study sample 
A sample is a part of a population selected by the researcher to participate in a research 
study (126). The sample size, sampling method, inclusion and exclusion criteria will be 
discussed. 
 
Sample size 
The contamination rates of multi-dose vials in the literature are inconsistent and range 
from 0% to 27% (63). The sample sizes of studies investigating the microbial 
contamination of multi-dose vials are between 96 and 637 (7, 9, 10, 26). Due to financial 
constraints the sample size of this study was limited to 110 samples. 
 
Sampling method 
A sampling method is the process of selecting a group of subjects from the population 
with which to conduct a study (125). Endacott et al (127) emphasises that it is more 
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important for the sample to accurately represent the population in quantitative research 
than it is to have a large sample. 
A convenience sampling method was used for this study. Brink (126) and Burns & Grove 
(125) described convenience sampling as choosing readily available subjects for the 
study until the desired sample size has been reached. The date and time of collection of 
the samples and labelling data was determined by the convenience for the data 
collector. This sampling method limited the bias caused by the Hawthorne effect.  
 
Inclusion and exclusion criteria 
Inclusion criteria for this study were:  
• the solutions found in the obstetric theatres at CHBAH.  
Exclusion criteria for this study were:   
• the solutions with < 10 ml of solution left in the container 
• any breach in the aseptic technique used during the collection and transportation 
of samples by the data collector.  
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3.5.4  Data collection 
Discussion of the data collection process will include data collected, the data collection 
process, the data collector and the data collection period. 
 
Data collected 
Samples taken from the solutions were sent to the National Health Laboratory Service 
(NHLS) for microbiological investigation. The labelling data on the solution containers 
were also documented. The following data were collected: 
• microbial contamination of the solutions 
• microorganisms isolated from the solutions 
• name and concentration of the solutions as documented on the containers 
• date and time the solutions was prepared as documented on the containers 
• if the healthcare workers that prepared the solutions confirmed it by signature on 
the containers 
• type of labelling method used on the solution containers (i.e. written directly on 
the container or label stuck on container) 
• method used to aspirate the solutions (i.e. puncturing the rubber septum of the 
container with a needle or using a spike-device). 
 
Data collection process 
The discussion on how the data was collected will include sample taking, sample 
labelling, sample storage and transport, sample processing at the laboratory and 
documentation of labelling data. 
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Sample taking: From each solution a sample was taken for microbiological investigation 
and the labelling data was also documented. All samples were collected and transported 
in a standardised manner. 
In consultation with a microbiologist it was decided that a 10 ml sample would be 
adequate for microbiological investigation. An aseptic technique was used to collect a 10 
ml sample from each solution container. This technique included: 
• washing hands before taking the sample 
•  wearing gloves while collecting the sample  
• using a new needle and syringe to aspirate each sample if the rubber septum 
needed to be punctured 
• using a new syringe to aspirate each sample directly from the spike-device if 
such a device was in situ  
• disinfecting the rubber septum or spike of each container with 70% isopropyl 
alcohol 
• waiting two minutes after disinfection to allow for drying of the disinfectant before 
aspirating the sample.  
An aerobic blood culture bottle (BacT/ALERT® SA) that has not past its expiration date, 
obtained from the National Health Laboratory Service (NHLS), was used to culture the 
solutions. The BacT/ALERT® SA blood culture bottle contains 40 ml supplemented 
tryptic soy broth as the culture media. The blood culture bottle was opened taking care 
not to contaminate the rubber septum. The bottle was then inoculated with the whole 10 
ml sample and gently rotated for 30 seconds to mix the sample and culture media.    
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Sample labelling: After inoculating the blood culture bottle with the sample, a standard 
NHLS investigation request form was completed for every sample (Appendix 4). Care 
was taken not to use any patient information.The information was recorded as follows: 
• Patient Hospital Number: The study number was written as dd-mm-yyyy-TH1/2. 
Where dd-mm-yyyy was the format in which the date the sample was taken on 
was recorded. The theatre from which the sample was taken was recorded as 
either theatre 1 (TH1) or theatre 2 (TH2). 
• Surname: Research 
• First name: Dr. A. van den Heever 
• Hospital / Clinic: CHBAH 
• Ward: Obstetric theatre 
• Diagnosis / Reason for request: Research 
• Type of specimen: Fluid 
• Date taken: dd-mm-yyyy 
• Time: hh:mm 
• Taken by: Dr. A. van den Heever 
• Requesting healthcare worker: Dr. A. van den Heever 
• HPCSA / SANC number: MP 0659029 
• Contact number: 083 415 4235 
• E-mail address: zanvdheever@iburst.co.za  
• Specimen Type: Fluid (specify) – Phenylephrine solution 
• Investigation required: Microscopy / Culture / Sensitivity 
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This data as well as the data concerning the labelling of the solutions were documented 
on a data collection form (Appendix 5).  
A unique peel-off barcode label from the NHLS investigation request form was attached 
to the blood culture bottle and the data collection form to facilitate the recovery of 
results. A unique peel-off barcode label on the blood culture bottle was attached to the 
NHLS investigation request form and the bar code number was documented on the data 
collection form.  
After collecting a sample for microbiological investigation and labelling data the relevant 
solution was discarded to avoid reuse.  
 
Sample storage and transport: An attempt was made to deliver the blood culture 
bottles to the Infection Control Services Laboratory, Department of Clinical Microbiology 
and Infectious Diseases, Witwatersrand School of Pathology, University of the 
Witwatersrand Medical school campus as soon as possible. If there was a delay in 
transporting the sample to the laboratory, it was stored at room temperature (20 - 25 °C) 
for not more than 12 hours. 
 
Sample processing at the laboratory: The processing of the samples and 
identification of the microorganisms were done by qualified laboratory personnel using 
standard microbiological laboratory equipment and procedures.  
The blood culture bottles were loaded into a BacT / ALERT 3D ® automated microbial 
detection system (manufactured by bioMérieux) as soon as it arrived at the laboratory. 
The cultures were incubated for five days whereafter the bottles with no microbial growth 
were deemed negative and were discarded. When a bottle signalled positive for 
microbial growth, broth from the bottle underwent Gram staining and was also 
subcultured onto agar plates. The agar plates were then reincubated until bacterial 
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growth occurred. Laboratory personnel then proceeded with the identification of the 
microorganism using standard microbiological methods.  
 
Documentation of labelling data: The labelling data on each solution container from 
which a sample was taken for microbiological investigation, was documented on a data 
collection form (Appendix 5). A standardised checklist, derived from labelling 
recommendations made by the Australian Commission on Safety and Quality in Health 
Care (120) was used to document the labelling data.  
 
Data collector 
All of the samples were collected in an aseptic manner and transported by the 
researcher. Labelling data was collected by the researcher using a predetermined 
checklist.  
 
Data collection period 
Data was collected over a period of three months, from October to December 2012. 
  
3.5.5 Data analysis 
Data capturing was done using an Excel 2007 spreadsheet (Appendix 3). Descriptive 
and inferential statistics were used to analyse the data. Statistical analysis was 
performed using GraphPad InStat, a statistics programme. A p-value of < 0.05 was 
considered as statistically significant. 
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3.6 Validity and reliability of the study 
Validity is the ability of an instrument to measure the variable that it is intended to 
measure (126). The measurement of the truth or accuracy of a claim is an important 
concern throughout the research process. Validity provides a basis for making decisions 
about which findings are useful for patient care (125). 
Reliability refers to the consistency and dependability of a research instrument to 
measure a variable (126).The reliability of a measure denotes the consistency of 
measures obtained from a particular instrument and indicates the extent of random error 
in the measurement method (125).  
The researcher collected, labelled, stored and transported all the samples in an aseptic 
manner. 
All the specimens were analysed at the Infection Control Services Laboratory, 
Department of Clinical Microbiology and Infectious Diseases, Witwatersrand School of 
Pathology, University of the Witwatersrand. The processing of the samples and 
identification of the microorganisms were done by qualified laboratory personnel using 
standard microbiological laboratory equipment and procedures. 
A predetermined, structured checklist was used to collect the labelling information from 
all of the solution containers. 
 
3.7 Conclusion 
In this chapter the problem statement, aims and objectives, ethical considerations, 
research methodology and the validity and reliability of this study were discussed. 
Discussion of the research methodology included the research design, study population, 
study sample, data collection and data analysis. In the next chapter, chapter 4, the 
results of this study will be discussed. 
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Chapter 4: Results and discussion 
4.1 Introduction 
In this chapter the sample realisation, the results of the study according to the objectives 
and a discussion regarding the results are presented. 
 
4.2  Sample realisation 
A total of 111 samples were collected from 1 October to 7 December 2012. One sample 
was excluded from the study due to a breach in the aseptic technique used during the 
collection and transportation of the sample by the researcher. The sample size of this 
study was therefore 110 samples. 
 
4.3 Results 
4.3.1 Determining whether there was any microbial contamination of 
the solutions and to identify the contaminating microorganisms 
Microbial contamination was identified in seven of 110 (6.36%) samples collected from 
the solutions. 
The contaminating microorganisms identified included coagulase negative staphylococci 
(2.72%), Brevundimonas vesicularis (0.91%), Bacillus species (0.91%), Micrococcus 
species (0.91%) and Pseudomonas alcaligenes (0.91%) (Table 4.1).  
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Table 4.1  Microbial contamination of the solutions 
Microorganisms Number of 
solutions 
contaminated 
(n) 
% 
Coagulase negative 
staphylococci 
3 2.72% 
Brevundimonas 
vesicularis 
1 0.91% 
Bacillus species 1 0.91% 
Micrococcus species 1 0.91% 
Pseudomonas 
alcaligenes 
1 0.91% 
Total 7 6.36% 
 
4.3.2 Evaluating whether the name and concentration of the solutions 
were documented on the containers 
The name of the solution was indicated on all (100%) of the containers from which 
samples were collected (Table 4.2).  
The concentration of the solution was indicated on 106 (96.36%) of the containers 
(Table 4.2).   
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Table 4.2 Labelling and aspiration practices with regards to the solutions 
Labelling and aspiration 
practice 
Number of 
solutions (n) 
% 
Name of solution 
indicated on container 
110 100% 
Concentration of 
solution indicated on 
container 
106 96.36% 
Date solution was 
prepared indicated on 
container 
82 74.55% 
Time solution was 
prepared indicated on 
container 
63 57.27% 
Healthcare worker that 
prepared solution 
confirmed it by placing a 
signature on the 
container 
9 8.18% 
Labelling data written 
directly on the container 
110 100% 
Spike-device used to 
aspirate solution from 
container 
71 64.54% 
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4.3.3 Evaluating whether the date and time the solutions were 
prepared was documented on the containers 
The date the solution was prepared was indicated on 82 (74.55%) of the 110 containers 
from which samples were collected (Table 4.2).  
The time the solution was prepared was indicated on 63 (57.27%) of the 110 containers 
from which samples were collected (Table 4.2).  
 
4.3.4 Evaluating whether the healthcare workers that prepared the 
solutions confirmed it by placing a signature on the containers 
The healthcare workers that prepared the solutions confirmed it by placing a signature 
on nine (8.18%) of the 110 containers from which samples were taken (Table 4.2).  
 
4.3.5 Evaluating the labelling method of the solutions (i.e. written 
directly on the container or label stuck on container) 
The labelling method used on all (100%) of the solutions was to write directly on the 
container (Table 4.2). 
 
4.3.6 Evaluating the aspiration method of the solutions (i.e. puncturing 
the rubber septum of the container with a needle or using a 
spike-device) 
A spike-device was used as the method of aspiration of the solution in 71 (64.54%) of 
the solutions from which samples were collected (Table 4.2). From the solutions that had 
microbial contamination, 6 (85,71%) had spike-devices in situ. Using Fisher’s exact test, 
the association between the aspiration method of the solution and microbial 
contamination of the solution was not statistically significant (p = 0.4178) (Table 4.3).  
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Table 4.3 Association between the aspiration method of the solution and microbial 
contamination of the solution 
 Microbial 
contamination 
No microbial 
contamination 
Total 
Spike-device 6 65 71 
No spike-device 1 38 39 
Total 7 103 110 
P = 0.4178 
 
4.4 Discussion 
4.4.1 Introduction 
The use of multi-dose vials in general and anaesthetic practice remains a controversial 
topic due to the risk of microbial contamination. Presently there are conflicting results 
reported in the literature (6, 8, 10, 18, 23, 25, 26, 58-62). The literature review suggested 
that the use of multi-dose vials does have a risk of microbial contamination if safe 
injection practices are not adhered to. Safe injection practices include the correct 
labelling and handling of medication containers (16, 29, 56). Currently SASA does not 
have an official standpoint on the use of multi-dose vials but it does not endorse the 
practice of sharing single-dose vials between multiple patients (109, 110). 
 
4.4.2 Microbial contamination of the solutions 
From the literature the microbial contamination rates of multi-dose vials range from 0% 
to 27% (63). Bacterial, viral, fungal and protozoal contamination of multi-dose vials have 
been reported (Chapter 2, Table 2.1). In contrast, recent studies have shown that multi-
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dose vials, and even single-dose vials used for multiple patients, can be used safely if 
safe injection and medication vial utilisation practices are adhered to (6, 18, 26, 61, 62).  
In this study seven of 110 samples (6.36%) were contaminated with microorganisms. 
This is similar to the results of Motamedifar et al (7) which reported a microbial 
contamination rate of 5.6%. It is however substantially higher than the microbial 
contamination rate of 0.9% reported by Mattner et al (10). This might not reflect the true 
microbial contamination rate since only contamination with aerobic bacteria was 
investigated in this study. It is clear from this study that safe injection practices with 
regard to the solution are not adhered to and that there is a relatively high risk for 
microbial contamination of the solution. This is of concern since patients are at risk of 
developing nosocomial infections when the solution is used. 
It has been shown that bacteria are common pathogens involved in the contamination of 
multi-dose vials and include Serratia marcescens, Enterobacter cloacae, Klebsiella 
pneumoniae, Ralstonia pickettii, Pseudomonas putida, Staphylococcus aureus and 
Staphylococcus epidermidis (Chapter 2, Table 2.1). The aerobic bacteria contaminating 
the solutions in this study include coagulase negative staphylococci (2.73%), 
Brevundimonas vesicularis (0.91%), Bacillus species (0.91%), Micrococcus species 
(0.91%) and Pseudomonas alcaligenes (0.91%). This is similar to the results of 
Motamedifar et al (7) and Mattner et al (10). 
Coagulase negative staphylococci are a group of microorganisms that are increasingly 
implicated as a cause of nosocomial infections (128, 129). Staphylococci are Gram-
positive cocci and are isolated primarily from mammals. There are 32 coagulase 
negative staphylococci species, 15 being common commensals in humans (129). Most 
of the staphylococci isolated from humans belong to the S. saprophyticus or the S. 
epidermidis group. The S. epidermidis group includes the species S. epidermidis, S. 
hominis, S. haemolyticus, S. warneri, S. caprae, S. saccharolyticus, S. pasteuri and S. 
lugdunensis (130). S. epidermidis is the predominant human species and is isolated 
from mucous membranes, moist habitats such as the groin and axilla as well as dry, 
exposed skin surfaces. Specific infections associated with coagulase negative 
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staphylococci include bacteremia, catheter-related infections, central nervous system 
shunt infections, endocarditis, urinary tract infection, surgical site infection and 
endophthalmitis. Due to financial limitations the specific coagulase negative 
staphylococci species were not identified in this study. 
Brevundimonas vesicularis  (B. vesicularis) is an aerobic, non-fermenting Gram-negative 
bacillus isolated from various sources including soil, bottled mineral water, hydrotherapy 
pools, shower hoses and human cervical specimens (131). Human infection with B. 
vesicularis is rare with only a few cases reported in the literature (132). Infections 
associated with B. vesicularis include bacteremia, pneumonia, infective endocarditis and 
spontaneous bacterial peritonitis. B. vesicularis is a pathogen that can cause 
opportunistic infections in immunocompromised patients (133).  
Members of the Bacillus species are aerobic, spore-forming, Gram-positive bacilli (134). 
The Bacillus species are commonly found in soil, on inanimate objects and on mucous 
membranes of humans (135). Over 30 species of Bacillus have been identified, with 
Bacillus cereus (B. cereus) and Bacillus anthracis (B. anthracis) being the most common 
pathogens. B. cereus is increasingly being recognised as a pathogen involved in 
opportunistic infections in hospitalised patients (136). Infections associated with Bacillus 
species include cutaneous infections, pneumonia, gastrointestinal infections, 
bacteremia, meningitis and endocarditis. 
Micrococcus species are catalase-positive, coagulase-negative, Gram-positive, aerobic 
cocci. Currently there are ten species of micrococci which include M. luteus, M. lylae, M. 
antarcticus, M. endophyticus, M. flavus, M. terreus, M. yunnanensis, M. lactis, M. 
niistensis and M. cohnii (137, 138). Micrococcus species are commonly found in soil, 
water, dust and the skin of humans and animals. Infections associated with Micrococcus 
species include bacteremia, endocarditis, ventriculitis, peritonitis, pneumonia, 
endophthalmitis, keratolysis, and septic arthritis (139). Recent studies have shown that 
Micrococcus species can be opportunistic pathogens in immunocompromised patients 
(140, 141). 
	  	  
55	  
Pseudomonas alcaligenes  (P. alcaligenes) is a Gram-negative, aerobic bacteria that 
has been placed in the Pseudomonas aeruginosa group (142). P. alcaligenes is isolated 
mainly from soil and water, rarely from clinical specimens (143). Infections associated 
with P. alcaligenes include bacteremia, endocarditis, otitis media, meningitis and wound 
infections. Recent studies have implicated P. alcaligenes in opportunistic infections in 
immunocompromised patients (144, 145).  
It is evident from the literature that the contaminating microorganisms identified in this 
study have been implicated as opportunistic pathogens in immunocompromised patients 
(133, 136, 140, 141, 144). This is especially important at CHBAH since a large 
proportion of South African patients are immunocompromised and susceptible to 
opportunistic infections (49).  
 
4.4.3 Labelling and aspiration practices of the solutions 
The literature shows that the inappropriate labelling of medication is a cause of 
medication administration errors in general (30, 31) and in anaesthetic practice (32-34). 
Labelling recommendations for medication containers include colour coded labels for 
different medication classes, patient name, patient hospital number, name of medication 
added to the container, amount of medication added, total volume of diluent in container, 
concentration of solution, date and time solution was prepared, solution prepared by, 
checked by, and route of administration (29, 120) 
In this study the name of the solution was indicated on all 110 (100%) containers from 
which samples were collected. This is similar to the results reported by Mattner et al (10) 
where the medication type was indicated on 99.12% of multi-dose vials. The 
concentration of the solution was indicated on 106 (96.36%) of the 110 containers which 
is similar to the 96.91% reported by Mattner et al (10). The date the solution was 
prepared was indicated on 82 (74.55%) of the 110 containers which is substantially 
higher than the 50% reported by Mattner et al (10). The time the solution was prepared 
was indicated on 63 (57.27%) of the 110 containers. It is clear from the results of the 
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study that the solutions are inappropriately labelled and that there is risk of an 
administration error when these solutions are used. 
Recommendations for correct medication labelling and administration are that the 
healthcare worker that prepared the medication should indicate it on the medication 
container (29, 120). In this study only 9 (8.18%) of the healthcare workers that prepared 
the solution confirmed it by placing a signature on the container. The majority of the 
solutions in the study were administered to patients without knowing who prepared the 
solution. This has medical-legal implications. 
Writing directly onto the container should be avoided as the ink can leach from the PVC 
container into the intravenous fluid and has been shown to be toxic to animals (121, 
123, 146). In this study the labelling data was written directly on all 110 (100%) 
containers from which samples were collected. This result shows that a potentially toxic 
solution is administered to patients. 
The APIC position paper on safe injection, infusion and medication vial practices in 
health care (56) strongly discourages the use of a spike-device inserted into a 
medication vial septum because it leaves the vial vulnerable to contamination. In this 
study a spike-device was used in 71 (64.54%) of the 110 containers from which samples 
were collected. This is substantially higher than the results reported by Mattner et all 
(10) where 41.41% of multi-dose vials had spike-devices. Although the association 
between the aspiration method of the solution and microbial contamination of the 
solution was not statistically significant (p = 0.4178), it must be noted that six of the 
seven contaminated solutions contained a spike-device. 
Medication labelling and administration is an important part of safe injection practices as 
shown in the literature. The results of this study clearly show that the solutions are 
inappropriately labelled and that a spike-device is commonly used to aspirate the 
solution. This is not in keeping with the recommendations for safe injection practices (29, 
56, 120). 
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4.4.4 Legal accountability of medication errors in South Africa 
An extensive research doctorate by Jansen (35) that comprehensively addresses 
various errors that can occur with regard to dispensing, preparation and administration 
of medication from a legal perspective, emphasises that healthcare workers experience 
a great deal of uncertainty with regard to their legal position and medication 
administration. Jansen (35) further concludes that healthcare workers do not view 
medication administration as the high risk activity that it is. 
An important medication error that anaesthetists are legally accountable for is the 
administration of contaminated medication (35). In this study seven (6.36%) solutions 
were contaminated and these contaminated solutions were administered to patients. All 
of the solutions were labelled by writing directly on the containers and therefore a 
potentially toxic solution was also administered to patients. As previously mentioned, a 
spike-device was used in 71 (64.54%) solutions, a method that is strongly discouraged 
as it leaves the vial vulnerable to contamination (56). 
Jansen (35) further states that a healthcare worker can only administer medication that 
was appropriately checked by the healthcare worker. This study did not evaluate if 
anaesthetists checked the solutions appropriately when it was prepared. However 101 
(91.82%) solutions had no signature indicating who had prepared the solution and 
anaesthetists were aspirating and administrating solutions from these containers. 
 
4.4.5 Significance of findings 
It is evident from the results of this study that the solutions used to treat hypotension, 
due to the vasodilatory effects of a spinal anaesthetic, in stable patients undergoing a 
caesarean section found in the obstetric theatres at CHBAH are at risk of microbial 
contamination due to unsafe injection practices when these solutions are prepared and 
administered. These solutions are also inappropriatly labelled, contributing to the risk of 
medication administration errors.  
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Unsafe injection practices expose patients to potentially harmful microorganisms. The 
contaminating microorganisms identified in this study have been implicated as 
opportunistic pathogens in immunocompromised patients (133, 136, 140, 141, 144). It is 
especially important at CHBAH since a large proportion of South African patients are 
immunocompromised and susceptible to opportunistic infections (49). 
Anaesthetists can be held legally accountable for medication errors. The medication 
errors identified in this study include administration of contaminated medication, 
administration of potentially toxic solutions and failing to appropriately check all 
medication prior to administration. Medication was administered without checking the 
date and time the medication was prepared, the concentration of the medication and 
verifying the healthcare worker that prepared the medication.  
 
4.5 Conclusion 
In this chapter the sample realisation, the results of the study and a discussion regarding 
the results was presented. In the final chapter, chapter 5, a study summary, the 
limitations of the study, recommendations and the conclusion of the study are discussed. 
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Chapter 5: Study summary, limitations, 
recommendations and conclusion 
5.1 Introduction 
In this final chapter a study summary, the limitations of the study, recommendations, and 
conclusion of the study are discussed. 
 
5.2 Study summary 
Anaesthetists are responsible for the safe use of anaesthetic-associated drugs (1). The 
use of multi-dose vials in the health care setting is controversial. The literature review 
suggested that the use of multi-dose vials poses a risk of microbial contamination if safe 
injection practices are not adhered to. Safe injection practices include the correct 
labelling and handling of medication containers. 
Common practice at CHBAH is to use boluses of a solution to treat hypotension, due to 
the vasodilatory effects of a spinal anaesthetic, in stable patients undergoing a 
caesarean section. This solution then acts as a multi-dose vial which is used for multiple 
patients. It has been observed that the solutions are often labelled incorrectly and strict 
aseptic technique is not always adhered to when using this solution as a multi-dose vial. 
This solution thus has the potential for microbial contamination as seven of the 110 
samples were contaminated. 
The aims of this study were to determine if there was microbial contamination of the 
solutions used at CHBAH and to evaluate if appropriate labelling practices were adhered 
to with regard to the solutions. 
Samples were collected from the solutions found in the two obstetric theatres at CHBAH. 
These samples were then used to inoculate aerobic blood culture bottles and were sent 
to the NHLS for microbiological investigation. The labelling data on the solutions from 
which samples were collected was documented on a data collection form. 
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A total of 111 samples were collected of which 110 met the inclusion criteria for this 
study. Microbial contamination was identified in seven of the 110 (6.36%) samples 
collected. Contaminating microorganisms included coagulase negative staphylococci 
(2.73%), B. vesicularis (0.91%), Bacillus species (0.91%), Micrococcus species (0.91%) 
and P. alcaligenes (0.91%). 
The name of the solution was indicated on all 110 (100%) containers from which 
samples were collected. The concentration of the solution was indicated on 106 
(96.36%) containers. The date the solution was prepared was indicated on 82 (74.55%) 
containers and the time the solution was prepared was indicated on 63 (57.27%) 
containers. Only nine (8.18%) of the healthcare workers that prepared the solution 
confirmed it by placing a signature on the container. The labelling data was written 
directly on all 110 (100%) containers. A spike-device was used in 71 (64.54%) 
containers from which samples were collected. 
 
5.3 Limitations 
This study was contextual and focused on the microbial contamination and labelling of a 
solution prepared and used by anaesthetists working in the two obstetric theatres at 
CHBAH. This limits the generalisation of the results. 
Due to financial constraints only microbial contamination with aerobic bacteria was 
investigated. Contamination of the samples with blood and other microorganisms 
(anaerobic bacteria, viruses, fungi, protozoa) was not assessed.   
There was concern that the Hawthorne effect (126) would influence the results of this 
study. This limitation was avoided by collecting samples and labelling data from the 
solutions on random days and at random times which were convenient for the 
researcher. Anaesthetists working at CHBAH were not informed about the study so as to 
prevent any change in their anaesthetic practice.  
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Convenience sampling was used to collect samples and data from the solutions. This 
can introduce bias as certain elements may be overrepresented or underrepresented. 
This makes generalisation based on such samples extremely risky, although the 
samples so chosen were convenient for the researcher in terms of time and money. 
Only categorical data was collected and therefore the association between the length of 
time the solution was in use and microbial contamination of the solution could not be 
investigated. 
 
5.4 Recommendations 
5.4.1 Recommendations for practice at the CHBAH theatre complex 
The use of multi-dose vials should be strongly discouraged at the CHBAH theatre 
complex as seven (6.36%) solutions were contaminated. 
If multi-dose vials are to be used due to financial or resource constraints, emphasis 
should be placed on the use of strict aseptic technique and only multi-dose vials 
containing bacteriostatic or bactericidal preservatives should be used.  
Spike-devices should not be left in the rubber septum of multi-dose vials. 
Guidelines with regards to the appropriate labelling of these solutions should be drawn 
up and implemented.  
Anaesthetists should prepare their own solutions and discard it at the end of their shifts. 
Healthcare workers should be educated about their legal position with regards to 
medication preparation and administration. 
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5.4.2 Recommendations for the pharmaceutical industry 
Pharmaceutical companies should consider manufacturing affordable, single-dose vials 
of commonly used medications at suitable concentrations for single use. 
The phenylephrine used at the CHBAH theatre complex is packaged in a 1 ml ampoule 
containing 10 mg/ml of phenylephrine. The phenylephrine needs to be diluted to 
produce an acceptable concentration that can be given as a bolus to treat hypotension 
in stable patients due to the vasodilatory effects of a general or regional anaesthetic. 
Pharmaceutical companies should consider manufacturing pre-filled phenylephrine 
syringes with an acceptable concentration that can be given as a bolus. 
  
5.4.3 Recommendations for formal guidelines regarding the use of 
multi-dose vials 
Local and international guidelines regarding the use of multi-dose vials in general and 
anaesthetic practice should be drawn up and implemented. 
SASA should consider taking an official standpoint on the use of multi-dose vials. This 
standpoint should then be published in the South African Journal of Anaesthesia and 
Analgesia (SAJAA) and implemented in state and private hospitals. 
 
5.4.4 Recommendations for further research 
Evaluate the cost-effectiveness of using single-dose vials compared to multi-dose vials.  
The financial and social burden of nosocomial infections due to the use of contaminated 
multi-dose vials should be evaluated. 
Evaluate the contamination of multi-dose vials with other microorganisms (anaerobic 
bacteria, viruses, fungi, protozoa) and blood. 
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5.5 Conclusion 
Common practice at CHBAH is to use boluses of a solution to treat hypotension, due to 
the vasodilatory effects of a spinal anaesthetic, in stable patients undergoing a 
caesarean section. This solution then acts as a multi-dose vial which is used for multiple 
patients. This study demonstrated microbial contamination of the solution and that safe 
injection practices were not adhered to when intravenous medications were prepared 
and administrated, which includes correct labelling practices. This is especially important 
at CHBAH since a large proportion of South African patients are immunocompromised 
and thus susceptible to opportunistic infections. An important medication error that 
anaesthetists are legally accountable for is the administration of contaminated 
medication. Furthermore inappropriate labelling of medications is a cause of medication 
administration errors and this may have serious legal implications for the anaesthetist. 
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Appendices 
Appendix 1 
Ethics clearance obtained from the Human Research Ethics Committee (Medical), 
University of the Witwatersrand 
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Appendix 2 
Approval for the conduction of this study obtained from the Postgraduate Office, Faculty 
of Health Sciences, University of the Witwatersrand 
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Appendix 3 
Permission to conduct this study at CHBAH obtained from the Medical Advisory 
Committee CHBAH 
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Appendix 4 
Standard NHLS investigation request form  completed for every sample collected in this 
study 
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Appendix 5 
Self-prepared, multi-dose phenylephrine solution data collection form 
 
Sample information 
Sample number  
NHLS request bar code number  
Blood culture bottle bar code number  
Date collected  
Time collected  
Theatre collected from Theatre 1 / Theatre 2 
	  
	  
Microbiological information 
Bacterial contamination Yes / No 
Organisms isolated  
 
 
Labelling information 
Name of solution indicated Yes / No 
Concentration of solution indicated Yes / No 
Date solution was prepared indicated Yes / No 
Time solution was prepared indicated Yes / No 
Signature of healthcare worker that 
prepared solution  
Yes / No 
Labelling method used Ink directly on container / Stick-on label / 
Other 
Spike-device Yes / No 
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Appendix 6 
Example of Excel spreadsheet for data analysis 
 
  
Sample 
number
NHLS 
request 
bar code 
number
Blood 
culture 
bottle bar 
code 
number
Date 
collected
Time 
collected
Theatre 
collected 
from (Th1/ 
Th2)
Bacterial 
contamina
tion (Yes/ 
No)
Organism
s isolated
Name of 
solution 
indicated 
(Yes/ No)
Concentra
tion of 
solution 
indicated 
(Yes/ No)
Date 
solution 
was 
prepared 
indicated 
(Yes/ No)
Time 
solution 
was 
prepared 
indicated 
(Yes/ No)
Signature 
of person 
who 
prepared 
solution 
(Yes/ No)
Labelling 
method 
used (Ink 
directly on 
container/ 
Stick-on 
label/ 
Other)
Spike 
device 
(Yes/ No)
01/10/2012-
TH1
BAYM7400
B
SAL75G3T 2012/10/01  6:40 Th 1 No Nil Yes Yes Yes No No Ink directly 
on 
container
Yes
01/10/2012-
TH2
BAYM7401
B
SAL75HC0 2012/10/01  6:55 Th 2 No Nil Yes Yes Yes No No Ink directly 
on 
container
Yes
02/10/2012-
TH1
BAYM7402
B
SAL75G6J 2012/10/02  6:50 Th 1 No Nil Yes Yes No No No Ink directly 
on 
container
Yes
02/10/2012-
TH2
BAYM7403
B
SAL75G1H 2012/10/02  7:05 Th 2 No Nil Yes Yes Yes No No Ink directly 
on 
container
No
03/10/2012-
TH1
BAYM7404
B
SAL75HB7 2012/10/03  6:50 Th 1 No Nil Yes Yes No No No Ink directly 
on 
container
No
03/10/2012-
TH2
BAYM7405
B
SAL75G5H 2012/10/03  7:00 Th 2 No Nil Yes Yes No No No Ink directly 
on 
container
No
04/10/2012-
TH1
BAYM7406
B
SAL75DQ6 2012/10/04  7:00 Th 1 No Nil Yes Yes Yes Yes No Ink directly 
on 
container
No
04/10/2012-
TH2
BAYM7407
B
SAL75G5
M
2012/10/04  7:15 Th 2 No Nil Yes Yes Yes Yes No Ink directly 
on 
container
Yes
05/10/2012-
TH1
BAYM7408
B
SAL75H9V 2012/10/05  6:50 Th 1 No Nil Yes Yes No No No Ink directly 
on 
container
No
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Appendix 7  
Quote for laboratory cost of the study 
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